ACETAMINOPHEN, ASPIRIN AND CAFFEINE

Post-LOE

acetaminophen, aspirin and caffeine

Aurobindo Pharma

ANDAORALTABLET

Approved

Feb 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

ACETAMINOPHEN, ASPIRIN AND CAFFEINE (acetaminophen, aspirin and caffeine) by Aurobindo Pharma is cyclooxygenase inhibitors [moa]. Approved for migraine. First approved in 2021.

Drug data last refreshed 20h ago

See 1 job working on ACETAMINOPHEN, ASPIRIN AND CAFFEINE →

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (1)

migraine

Clinical Trials (1)

NCT01248468Phase 4Completed

Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine

Started Nov 2010

752 enrolled

Pain, Migraine

Why This Matters for Your Career

Worked on ACETAMINOPHEN, ASPIRIN AND CAFFEINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.